The use of 7T MRI in multiple sclerosis: review and consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

• Published in: Brain communications 2024, Vol.6 (5), p.fcae359
• Main Authors: Harrison, Daniel M, Sati, Pascal, Klawiter, Eric C, Narayanan, Sridar, Bagnato, Francesca, Beck, Erin S, Barker, Peter, Calvi, Alberto, Cagol, Alessandro, Donadieu, Maxime, Duyn, Jeff, Granziera, Cristina, Henry, Roland G, Huang, Susie Y, Hoff, Michael N, Mainero, Caterina, Ontaneda, Daniel, Reich, Daniel S, Rudko, David A, Smith, Seth A, Trattnig, Siegfried, Zurawski, Jonathan, Bakshi, Rohit, Gauthier, Susan, Laule, Cornelia
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2632-1297; 2632-1297
• DOI: 10.1093/braincomms/fcae359

The use of ultra-high-field 7-Tesla (7T) MRI in multiple sclerosis (MS) research has grown significantly over the past two decades. With recent regulatory approvals of 7T scanners for clinical use in 2017 and 2020, the use of this technology for routine care is poised to continue to increase in the coming years. In this context, the North American Imaging in MS Cooperative (NAIMS) convened a workshop in February 2023 to review the previous and current use of 7T technology for MS research and potential future research and clinical applications. In this workshop, experts were tasked with reviewing the current literature and proposing a series of consensus statements, which were reviewed and approved by the NAIMS. In this review and consensus paper, we provide background on the use of 7T MRI in MS research, highlighting this technology's promise for identification and quantification of aspects of MS pathology that are more difficult to visualize with lower-field MRI, such as grey matter lesions, paramagnetic rim lesions, leptomeningeal enhancement and the central vein sign. We also review the promise of 7T MRI to study metabolic and functional changes to the brain in MS. The NAIMS provides a series of consensus statements regarding what is currently known about the use of 7T MRI in MS, and additional statements intended to provide guidance as to what work is necessary going forward to accelerate 7T MRI research in MS and translate this technology for use in clinical practice and clinical trials. This includes guidance on technical development, proposals for a universal acquisition protocol and suggestions for research geared towards assessing the utility of 7T MRI to improve MS diagnostics, prognostics and therapeutic efficacy monitoring. The NAIMS expects that this article will provide a roadmap for future use of 7T MRI in MS.